Lazari Capital Management Inc. Grows Stake in Pfizer Inc. (NYSE:PFE)

Lazari Capital Management Inc. grew its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 93.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 62,380 shares of the biopharmaceutical company's stock after purchasing an additional 30,151 shares during the period. Lazari Capital Management Inc.'s holdings in Pfizer were worth $1,581,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in PFE. Legacy Advisors LLC raised its position in shares of Pfizer by 7.1% in the 1st quarter. Legacy Advisors LLC now owns 64,203 shares of the biopharmaceutical company's stock valued at $1,627,000 after purchasing an additional 4,243 shares during the last quarter. AssuredPartners Investment Advisors LLC increased its stake in Pfizer by 49.6% during the 1st quarter. AssuredPartners Investment Advisors LLC now owns 60,969 shares of the biopharmaceutical company's stock valued at $1,545,000 after purchasing an additional 20,210 shares in the last quarter. GHP Investment Advisors Inc. raised its holdings in shares of Pfizer by 12.6% in the first quarter. GHP Investment Advisors Inc. now owns 13,523 shares of the biopharmaceutical company's stock worth $343,000 after buying an additional 1,517 shares during the last quarter. Asset Management One Co. Ltd. lifted its stake in shares of Pfizer by 6.8% during the first quarter. Asset Management One Co. Ltd. now owns 2,556,028 shares of the biopharmaceutical company's stock worth $64,770,000 after buying an additional 163,269 shares during the period. Finally, Blossom Wealth Management grew its holdings in shares of Pfizer by 16.4% during the first quarter. Blossom Wealth Management now owns 15,153 shares of the biopharmaceutical company's stock valued at $384,000 after buying an additional 2,131 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of research reports. Cantor Fitzgerald started coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target for the company. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, UBS Group increased their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Pfizer has an average rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Stock Performance

PFE opened at $24.04 on Tuesday. The firm has a fifty day moving average price of $23.30 and a 200 day moving average price of $24.88. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The stock has a market cap of $136.68 billion, a P/E ratio of 17.42, a P/E/G ratio of 0.87 and a beta of 0.57. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter in the previous year, the company earned $0.82 earnings per share. The firm's revenue for the quarter was down 7.8% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.15%. Pfizer's dividend payout ratio is currently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.